General Statement of Disclosure:

CONSULTING FEES/HONORARIA: American Board of Internal Medicine(MODEST), Bayer(MODEST), AstraZeneca Pharmaceuticals(SIGNIFICANT), Novartis(SIGNIFICANT), Merck(MODEST), Ionis(MODEST), Pfizer(MODEST), Lilly Medical (MODEST), Novo Nordisk Inc.(MODEST), Amgen(MODEST), Aria(MODEST), Axon(MODEST), Bristol-Myers Squibb Company (MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Cardiora(MODEST), Cyclerion(MODEST), Cytokinetics (MODEST), Eisai(MODEST), GSK(MODEST), Imara(MODEST), Ironwood (MODEST), Keyto(MODEST), MyoKardia(MODEST), Regeneron(MODEST), Sanofi(MODEST), Shifamed(MODEST), United Therapeutics (MODEST), Boston Scientific (MODEST), Abbott (MODEST), CVRx(MODEST), ekoi.ai(MODEST), Janssen(MODEST), Prothena(MODEST), Tenax(MODEST) SPEAKER'S BUREAU: Pulmonary Hypertension Association(MODEST) RESEARCH/RESEARCH GRANTS: National Institutes of Health(SIGNIFICANT), Actelion(SIGNIFICANT), American Heart Association(SIGNIFICANT), Corvia(SIGNIFICANT)

View Full Disclosure